drugset / Trial / NCT03772964

Effects of Metformin in a Non-Diabetic Patient Population

NCT03772964

Phase 1/2 Completed 32 enrolled Brian Zuckerbraun
RandomizedParallel-groupTriple-blindBasic science

Summary

Metformin has a well-established safety profile and it has become clear that metformin has additional salutary effects, including anti-inflammatory, anti-aging, and anti-thrombotic properties. In this study, subjects will provide both venous blood samples and stool samples in addition to completing cognitive and physiologic testing at baseline, throughout a 90 day exposure to metformin, and 30 days following exposure to metformin in order to evaluate their immune, microbiome, cellular respiration, thrombotic, and inflammatory responses.

Timeline

Start
2019-01-22
Primary completion
2020-03-31
Completion
2020-03-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg
Subject Metformin Small molecule 1000 mg
Subject Metformin Small molecule 1500 mg

Indications